Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Mol Genet ; 30(6): 485-499, 2021 04 30.
Article in English | MEDLINE | ID: mdl-33693707

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with high mortality. The cellular origins of PDAC are largely unknown; however, ductal cells, especially centroacinar cells (CACs), have several characteristics in common with PDAC, such as expression of SOX9 and components of the Notch-signaling pathway. Mutations in KRAS and alterations to Notch signaling are common in PDAC, and both these pathways regulate the transcription factor SOX9. To identify genes regulated by SOX9, we performed siRNA knockdown of SOX9 followed by RNA-seq in PANC-1s, a human PDAC cell line. We report 93 differentially expressed (DE) genes, with convergence on alterations to Notch-signaling pathways and ciliogenesis. These results point to SOX9 and Notch activity being in a positive feedback loop and SOX9 regulating cilia production in PDAC. We additionally performed ChIP-seq in PANC-1s to identify direct targets of SOX9 binding and integrated these results with our DE gene list. Nine of the top 10 downregulated genes have evidence of direct SOX9 binding at their promoter regions. One of these targets was the cancer stem cell marker EpCAM. Using whole-mount in situ hybridization to detect epcam transcript in zebrafish larvae, we demonstrated that epcam is a CAC marker and that Sox9 regulation of epcam expression is conserved in zebrafish. Additionally, we generated an epcam null mutant and observed pronounced defects in ciliogenesis during development. Our results provide a link between SOX9, EpCAM and ciliary repression that can be exploited in improving our understanding of the cellular origins and mechanisms of PDAC.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Pancreatic Ductal/pathology , Cilia/genetics , Epithelial Cell Adhesion Molecule/metabolism , Pancreatic Neoplasms/pathology , SOX9 Transcription Factor/metabolism , Animals , Biomarkers, Tumor/genetics , Carcinoma, Pancreatic Ductal/genetics , Carcinoma, Pancreatic Ductal/metabolism , Cell Movement , Cell Proliferation , Cilia/metabolism , Epithelial Cell Adhesion Molecule/genetics , Humans , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , SOX9 Transcription Factor/genetics , Signal Transduction , Zebrafish
2.
Dev Biol ; 418(1): 28-39, 2016 10 01.
Article in English | MEDLINE | ID: mdl-27565026

ABSTRACT

Centroacinar cells (CACs) are ductal Notch-responsive progenitors that in the larval zebrafish pancreas differentiate to form new islets and ultimately contribute to the majority of the adult endocrine mass. Uncovering the mechanisms regulating CAC differentiation will facilitate understanding how insulin-producing ß cells are formed. Previously we reported retinoic acid (RA) signaling and Notch signaling both regulate larval CAC differentiation, suggesting a shared downstream intermediate. Sox9b is a transcription factor important for islet formation whose expression is upregulated by Notch signaling in larval CACs. Here we report that sox9b expression in larval CACs is also regulated by RA signaling. Therefore, we hypothesized that Sox9b is an intermediate between both RA- and Notch-signaling pathways. In order to study the role of Sox9b in larval CACs, we generated two cre/lox based transgenic tools, which allowed us to express full-length or truncated Sox9b in larval CACs. In this way we were able to perform spatiotemporal-controlled Sox9b gain- and loss-of-function studies and observe the subsequent effect on progenitor differentiation. Our results are consistent with Sox9b regulating CAC differentiation by being a downstream intermediate of both RA- and Notch-signaling pathways. We also demonstrate that adult zebrafish with only one functional allele of sox9b undergo accelerated ß-cell regeneration, an observation consistent with sox9b regulating CAC differentiation in adults.


Subject(s)
Cell Differentiation/genetics , Insulin-Secreting Cells/cytology , Pancreas/embryology , SOX9 Transcription Factor/genetics , Tretinoin/metabolism , Zebrafish Proteins/genetics , Zebrafish/embryology , Alleles , Animals , Blood Glucose/genetics , Cell Differentiation/physiology , Cell Movement/genetics , Cell Movement/physiology , Larva/growth & development , Receptors, Notch/metabolism , Regeneration/genetics , SOX9 Transcription Factor/metabolism , Signal Transduction , Zebrafish Proteins/metabolism
3.
J Med Chem ; 59(1): 206-18, 2016 Jan 14.
Article in English | MEDLINE | ID: mdl-26629713

ABSTRACT

Radiolabeled urea-based low-molecular weight inhibitors of the prostate-specific membrane antigen (PSMA) are under intense investigation as imaging and therapeutic agents for prostate and other cancers. In an effort to provide agents with less nontarget organ uptake than the ureas, we synthesized four (18)F-labeled inhibitors of PSMA based on carbamate scaffolds. 4-Bromo-2-[(18)F]fluorobenzoyllysineoxypentanedioic acid (OPA) carbamate [(18)F]23 and 4-iodo-2-[(18)F]fluorobenzoyllysine OPA carbamate [(18)F]24 in particular exhibited high target-selective uptake in PSMA+ PC3 PIP tumor xenografts, with tumor-to-kidney ratios of >1 by 4 h postinjection, an important benchmark. Because of its high tumor uptake (90% injected dose per gram of tissue at 2 h postinjection) and high tumor-to-organ ratios, [(18)F]23 is promising for clinical translation. Prolonged tumor-specific uptake demonstrated by [(18)F]24, which did not reach equilibrium during the 4 h study period, suggests carbamates as alternative scaffolds for mitigating dose to nontarget tissues.


Subject(s)
Carbamates/chemical synthesis , Carbamates/pharmacology , Pentanoic Acids/chemical synthesis , Pentanoic Acids/pharmacology , Positron-Emission Tomography/methods , Prostate-Specific Antigen/metabolism , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/pharmacology , Animals , Carbamates/pharmacokinetics , Cell Line, Tumor , Drug Stability , Female , Fluorine Radioisotopes , Humans , Kidney/diagnostic imaging , Male , Mice , Mice, SCID , Molecular Docking Simulation , Organ Specificity , Prostate/diagnostic imaging , Radiopharmaceuticals/pharmacokinetics , Tissue Distribution , Xenograft Model Antitumor Assays
4.
Chemistry ; 20(48): 15824-32, 2014 Nov 24.
Article in English | MEDLINE | ID: mdl-25302635

ABSTRACT

The optimal exchange properties for chemical exchange saturation transfer (CEST) contrast agents on 3 T clinical scanners were characterized using continuous wave saturation transfer, and it was demonstrated that the exchangeable protons in phenols can be tuned to reach these criteria through proper ring substitution. Systematic modification allows the chemical shift of the exchangeable protons to be positioned between 4.8 to 12 ppm from water and enables adjustment of the proton exchange rate to maximize CEST contrast at these shifts. In particular, 44 hydrogen-bonded phenols are investigated for their potential as CEST MRI contrast agents and the stereoelectronic effects on their CEST properties are summarized. Furthermore, a pair of compounds, 2,5-dihydroxyterephthalic acid and 4,6-dihydroxyisophthalic acid, were identified which produce the highest sensitivity through incorporating two exchangeable protons per ring.


Subject(s)
Hydrogen/chemistry , Phenols/chemistry , Phthalic Acids/chemistry , Contrast Media/chemistry , Hydrogen Bonding , Magnetic Resonance Imaging
5.
PLoS One ; 8(6): e66357, 2013.
Article in English | MEDLINE | ID: mdl-23840449

ABSTRACT

The bony shell of the turtle is an evolutionary novelty not found in any other group of animals, however, research into its formation has suggested that it has evolved through modification of conserved developmental mechanisms. Although these mechanisms have been extensively characterized in model organisms, the tools for characterizing them in non-model organisms such as turtles have been limited by a lack of genomic resources. We have used a next generation sequencing approach to generate and assemble a transcriptome from stage 14 and 17 Trachemys scripta embryos, stages during which important events in shell development are known to take place. The transcriptome consists of 231,876 sequences with an N50 of 1,166 bp. GO terms and EC codes were assigned to the 61,643 unique predicted proteins identified in the transcriptome sequences. All major GO categories and metabolic pathways are represented in the transcriptome. Transcriptome sequences were used to amplify several cDNA fragments designed for use as RNA in situ probes. One of these, BMP5, was hybridized to a T. scripta embryo and exhibits both conserved and novel expression patterns. The transcriptome sequences should be of broad use for understanding the evolution and development of the turtle shell and for annotating any future T. scripta genome sequences.


Subject(s)
Gene Expression Profiling/methods , High-Throughput Nucleotide Sequencing/methods , Sequence Analysis, RNA/methods , Turtles/embryology , Animals , Biological Evolution , Gene Expression Regulation, Developmental , Gene Regulatory Networks , Turtles/genetics
6.
Cancer Cell ; 23(3): 302-15, 2013 Mar 18.
Article in English | MEDLINE | ID: mdl-23477830

ABSTRACT

Activating mutations in BRAF are the most common genetic alterations in melanoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis. We show here that BRAF inhibition also induces an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1α. We further show that a target of BRAF, the melanocyte lineage factor MITF, directly regulates the expression of PGC1α. Melanomas with activation of the BRAF/MAPK pathway have suppressed levels of MITF and PGC1α and decreased oxidative metabolism. Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to oxidative phosphorylation. Our data thus identify an adaptive metabolic program that limits the efficacy of BRAF inhibitors.


Subject(s)
Heat-Shock Proteins/metabolism , Melanoma/metabolism , Microphthalmia-Associated Transcription Factor/metabolism , Proto-Oncogene Proteins B-raf/metabolism , Transcription Factors/metabolism , Apoptosis , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Heat-Shock Proteins/genetics , Humans , Indoles/pharmacology , Melanocytes/metabolism , Melanoma/genetics , Mitochondria/metabolism , Mitogen-Activated Protein Kinases/metabolism , Mutation , Oxidative Phosphorylation , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , RNA, Messenger/biosynthesis , Signal Transduction , Sulfonamides/pharmacology , Transcription Factors/genetics , Vemurafenib
SELECTION OF CITATIONS
SEARCH DETAIL
...